On November 5, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,463,724 titled "Breast Cancer Vaccine (Press release, Anixa Biosciences, NOV 5, 2019, View Source [SID1234550308])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The lead inventor on the patent is Dr. Vincent Tuohy of the Department of Inflammation and Immunity at the Cleveland Clinic’s Lerner Research Institute and also the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research. The patent is assigned to the Cleveland Clinic and Anixa Biosciences is the exclusive world-wide licensee. This patent is one of several patents and patent applications in the portfolio licensed to Anixa Biosciences from the Cleveland Clinic, covering the innovative breast cancer vaccine technology.

"We are pleased that this key patent has been issued for technology, which we hope may eliminate breast cancer," stated Dr. Amit Kumar, Chief Executive Officer of Anixa. "This patent covers Dr. Tuohy’s method of protecting women from developing breast cancer by vaccinating against a protein that is "retired" from service after a woman has stopped lactating, only to reappear later in life in many forms of breast cancer, especially triple negative breast cancer (TNBC), the most lethal form of the disease. We look forward to progressing towards major breakthroughs in the prevention of breast cancer."